Children with sickle cell disease (SCD) exposed to higher doses of the oral therapy hydroxyurea report better blood-related…
Articles by Marisa Wexler, MS
The gene editing therapy EDIT-301 appears to be working as intended in the first person with sickle cell disease…
Note: This story has been updated July 19, 2022, to correct that voxelotor is approved in the U.S.
Two mouse models commonly used to study sickle cell disease (SCD) are not suitable for testing certain gene editing…
A novel strategy called Engineered Stem Cell Antibody Paired Evasion (ESCAPE) could be used to more safely prepare people with…
Global Blood Therapeutics (GBT) has begun a Phase 2/3 trial to study the safety, tolerability, effectiveness, and pharmacological properties…
Aflac, a U.S. supplemental health insurance company, has given $100,000 to Children’s National Hospital in Washington, D.C., to support research…
The U.S. Food and Drug Administration (FDA) has granted both orphan drug and rare pediatric disease designations to inclacumab and…
Hemex Health’s portable point-of-care device, Gazelle, is being enhanced to more precisely monitor fetal hemoglobin levels. According to…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…